

Title (en)  
RECOMBINANT PRODUCT

Publication  
**EP 0446315 A4 19920805 (EN)**

Application  
**EP 90912919 A 19900904**

Priority  
• AU 9000396 W 19900904  
• AU PJ617989 A 19890905

Abstract (en)  
[origin: WO9103556A1] This invention relates to PAI-2 and its expression as a recombinant molecule in eukaryotic cell lines as a glycosylated secreted molecule, to the constructs expressing it, to host cells expressing it, to compositions comprising it, to methods of treatment, prophylaxis and diagnosis using it and to antibodies raised against it. The invention also provides a 414 amino acid form of PAI-2 wherein the N-terminal methionine residue is deleted, a 60 kD glycosylated secreted recombinant form of PAI-2 and compositions and methods using these molecules. The invention further relates to a novel synthetic signal peptide.

IPC 1-7  
**C12N 15/15**; **C12N 15/11**; **C12N 15/64**; **C12N 5/10**; **C12P 21/02**; **C07K 13/00**; **C07K 7/08**; **C07K 15/12**; **G01N 33/574**; **G01N 33/531**; **A61K 37/64**

IPC 8 full level  
**G01N 33/53** (2006.01); **A61K 38/55** (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **A61K 49/00** (2006.01); **A61K 51/00** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/04** (2006.01); **A61P 43/00** (2006.01); **C07K 7/08** (2006.01); **C07K 14/00** (2006.01); **C07K 14/81** (2006.01); **C07K 16/00** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/15** (2006.01); **C12N 15/62** (2006.01); **C12P 21/00** (2006.01); **C12P 21/08** (2006.01); **G01N 33/577** (2006.01); **A61K 38/00** (2006.01); **C12R 1/91** (2006.01)

CPC (source: EP KR US)  
**A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 14/8132** (2013.01 - EP US); **C12N 15/11** (2013.01 - KR); **C12N 15/625** (2013.01 - EP US); **A61K 38/00** (2013.01 - EP US); **C07K 2319/02** (2013.01 - EP US); **C07K 2319/036** (2013.01 - EP US); **C07K 2319/91** (2013.01 - EP US)

Citation (search report)  
• [XY] EP 0278696 A2 19880817 - NEW ENGLAND MEDICAL CENTER INC [US], et al  
• [XY] DE 3713272 A1 19881103 - BEHRINGWERKE AG [DE]  
• [Y] FR 2611723 A1 19880909 - TRANSGENE SA [FR]  
• [XY] R. YE ET AL: "Mammalian protein secretion without signal peptide removal", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 263, no. 10, 5 April 1988 (1988-04-05), BALTIMORE US, pages 4869 - 4875  
• [XY] R. YE ET AL: "cDNA cloning and expression in E. coli of a plasminogen activator inhibitor from human placenta", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 262, no. 8, 15 March 1987 (1987-03-15), BALTIMORE US, pages 3718 - 3725  
• [Y] PATENT ABSTRACTS OF JAPAN vol. 13, no. 29 (C - 526)<3377> 23 January 1989 (1989-01-23)  
• [A] E. LAWRENCE: "Henderson's dictionary of Biological Terms", 1989, LONGMAN SCIENTIFIC & TECHNICAL, AVON, GB, 164750  
• [PA] S. ALI ET AL: "Characterisation of the alleles encoding ovine beta -lactoglobins A and B", GENE., vol. 91, 16 July 1990 (1990-07-16), AMSTERDAM NL, pages 201 - 207  
• See references of WO 9103556A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB IT LI LU NL SE

DOCDB simple family (publication)  
**WO 9103556 A1 19910321**; AT E154362 T1 19970615; AU 6283190 A 19910408; AU 629980 B2 19921015; CA 2041638 A1 19910306; CA 2041638 C 20010515; DE 69030920 D1 19970717; DE 69030920 T2 19980219; DK 0446315 T3 19980105; EP 0446315 A1 19910918; EP 0446315 A4 19920805; EP 0446315 B1 19970611; ES 2104610 T3 19971016; JP H04502108 A 19920416; KR 920701436 A 19920811; NZ 235182 A 19930127; US 5298400 A 19940329

DOCDB simple family (application)  
**AU 9000396 W 19900904**; AT 90912919 T 19900904; AU 6283190 A 19900904; CA 2041638 A 19900904; DE 69030920 T 19900904; DK 90912919 T 19900904; EP 90912919 A 19900904; ES 90912919 T 19900904; JP 51195690 A 19900904; KR 910700435 A 19910430; NZ 23518290 A 19900905; US 67905291 A 19910506